Form D · Biotechnology

Clover Biopharmaceuticals, Ltd.

Chengdu, F4 · CIK 0001856491

Offering snapshot reported Apr 29, 2026 · SEC filing

Reported sold
$3.64M
Offering amount: $3.64M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 27, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 29, 2026Initial$3,642,978No comparison9SEC filing
Apr 28, 2025Amendment$904,859$584,146vs Apr 12, 202413SEC filing
Apr 12, 2024Initial$320,713No comparison10SEC filing
May 9, 2023Amendment$48,882,447$10,810,804vs Apr 28, 202174SEC filing
May 24, 2022Amendment$48,123,054$10,051,411vs Apr 28, 202138SEC filing
Apr 28, 2021Initial$38,071,643No comparison27SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-582300

Source: Form D, filed Apr 29, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Peng Liang Director, Executive, Promoter
Joshua Liang Director, Executive
Dong Lyu Director
Xiaodong Wang Director
Ting Xiao Director
Guangyu Xu Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
B5 19,Building,High Tech Incubation Park No. 1480 North Section Of Tianfu Avenue
Chengdu, F4, 610041